Your search

  • Dr Pirooz Poursoltan

    Speciality: Medical Oncology

    Team: Breast Oncology, Colorectal Oncology, Lung Oncology

    Address 1: Macquarie University Clinic Suite 302, Level 3

    Address 2: 2 Technology Place , Macquarie University, NSW, 2109

    Phone: 02 9887 8899

    Fax: 02 9887 8800

    - Hide Biography + Read Biography
    Dr Poursoltan is a medical oncologist with a special interest in gastro-intestinal, lung and breast cancers. He worked at Royal North Shore Hospital and has been practising at Macquarie University Hospital since 2011. Dr Poursoltan holds a Master of Science in Medicine from The University of Sydney. He has also taken extra training in genetics with interest in Molecular biology of lung cancer, during which he worked on the genes potentially involved in the pathogenesis of lung cancer. Dr Poursoltan has worked at the Garvan Institute and University of Sydney.
  • Professor Howard Gurney

    Speciality: Medical Oncology

    Subspeciality: Genitourinary Cancers, Prostate Cancer, Lymphoma

    Team: Uro-oncology

    Address 1: Macquarie University Urology Macquarie University Clinic

    Address 2: Suite 304, Level 3 2 Technology Place , Macquarie University, NSW, 2109

    Phone: 02 8850 8100

    - Hide Biography + Read Biography
    Howard Gurney is the Director of Medical Oncology and Clinical Research at Macquarie University Hospital. He is a Clinical Associate Professor at both Macquarie University and University of Sydney. He also is a medical oncologist at Westmead Hospital. Professor Gurney has a firm background in clinical research and has subspecialty interests in lymphoma and uro-genital cancers including prostate, bladder, testis and kidney cancer. He has been principle investigator for over 150 phase 2 and 3 clinical studies. Current research interests include the pharmacogenomics and therapeutic monitoring of chemotherapy and targeted therapies and he has published widely in this area. He is regarded as a world authority on mechanisms for safe dosing of anticancer agents and has written a number of invited editorials on this topic for the Lancet Oncology and the Journal of Clinical Oncology.